PharVision Advisers’s Ecolab ECL Stock Holding History

PharVision Advisers’s Portfolio ECL Stock Details ECL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-946	Closed	-$248K	–	268
2025 Q4	$248K	Buy	+946	New	+$252K	0.13%	393

Other funds holding ECL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gates Foundation Trust Kirkland, Washington $31.7B AUM 20.52% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

PharVision Advisers's ECL Position: Q1 2026 in Review

PharVision Advisers sold out of Ecolab (ECL) in Q1 2026, closing a stake of 946 shares — an estimated $248K sold.

PharVision Advisers first reported a position in ECL in Q4 2025 and held it in 1 quarter. The position peaked at $248K in Q4 2025. 1,693 funds tracked by Wall St. Rank hold ECL as of Q1 2026.

PharVision Advisers reported no remaining Ecolab position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 946 Ecolab shares in Q1 2026, an estimated $248K.
PharVision Advisers first reported a position in Ecolab in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Ecolab position peaked at $248K in Q4 2025.
1,693 funds tracked by Wall St. Rank held Ecolab as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.